Prognostic impact of secondary prevention after coronary artery bypass grafting-insights from the TiCAB trial.
Heer T, von Scheidt M, Boening A, Heyken C, Gusmini F, de Waha A, Kuna C, Fach A, Grothusen C, Oberhoffer M, Knosalla C, Walther T, Danner BC, Misfeld M, Wimmer-Greinecker G, Siepe M, Grubitzsch H, Joost A, Schaefer A, Conradi L, Cremer J, Hamm C, Lange R, Radke PW, Schulz R, Laufer G, Grieshaber P, Attmann T, Schmoeckel M, Meyer A, Ziegelhöffer T, Hambrecht R, Sandner SE, Kastrati A, Schunkert H, Zeymer U.
Heer T, et al. Among authors: grieshaber p.
Eur J Cardiothorac Surg. 2022 Aug 3;62(3):ezac048. doi: 10.1093/ejcts/ezac048.
Eur J Cardiothorac Surg. 2022.
PMID: 35138350
Clinical Trial.